Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Bayer receives NICE approval for Stivarga in treatment of GIST

Bayer receives NICE approval for Stivarga in treatment of GIST

13th October 2017

Bayer has announced that its cancer drug Stivarga has been recommended for routine NHS use as a treatment for gastrointestinal stromal tumours (GIST).

The UK's National Institute for Health and Clinical Excellence has issued a positive recommendation for Stivarga for use in the treatment of adult patients with unresectable or metastatic GIST who have progressed on, or are intolerant to, prior treatment with imatinib and sunitinib.

Stivarga has been available for patients with GIST on the Cancer Drugs Fund since 2013, but this decision will mean cancer patients who have failed to respond to previous therapies will now have routine access to the treatment.

This decision was based on positive clinical data showing the safety and efficacy of the drug in this indication.

Lars Bruening, chief executive of Bayer for the UK and Ireland, said: "Patients have limited treatment options and this news means they will have access to another line of effective therapy, as soon as it is adopted by policymakers."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.

We currently have 8 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.